ValGenesis, Inc., a company involved in validation lifecycle management systems (VLMS), has entered into a partnership with one of the top 5 global cell and gene therapy manufacturers. The company opted for the ValGenesis digital validation platform for its validation processes globally, to improve the quality and efficiency of CAR-T therapy production.

ValGenesis VLMS is a digital solution designed to manage the entire validation lifecycle for this global manufacturer.

According to the company, transitioning from traditional paper-based methods to a fully digital framework marks a milestone in operational efficiency and traceability.

Steve Reynolds, chief revenue officer at ValGenesis, said, “Our platform’s adaptability and highly configurable features allow life science organizations to deploy solutions at single locations and then expand them globally. It enables remote, real-time monitoring of validation activities, promoting consistency and standardization in the validation programs across global sites, which helps reduce costs and cycle time.”